Evaluasi Penggunaan Antidiabetik Pasien Diabetes Melitus Tipe 2 di Puskesmas Banguntapan 1

Drug Use Evaluation of Antidiabetic in Type 2 Diabetes Mellitus Patients at One of the Public Health Care in Bantul Regency

Authors

  • Qarriy Aina Urfiyya Program Studi DIII Farmasi, Akademi Farmasi Indonesia Yogyakarta, Indonesia
  • Ayu Rafi Azizah Puskesmas Banguntapan 1, Yogyakarta, Indonesia

DOI:

https://doi.org/10.25026/jsk.v7i2.2402

Abstract

Diabetes mellitus (DM) is a metabolic disease that can cause damage to several organs. IDF projects an increase in DM by 2045 to 46%. The study aimed to evaluate the treatment of patients with type 2 DM and the potential for drug interactions. The research design was observational and retrospective data collection on prescriptions and medical records of type 2 DM patients at Banguntapan 1 Health Center, January- February 2023, a total of 125. The results of the study were that most type 2 DM patients were female gender (62%), age 46-65 years (70%), and hypertension comorbidities (78%). The most widely used antidibetic was the metformin-glimepiride combination (83%). The conclusions of the study were dose accuracy (100%), accuracy of the time interval of administration (98.4%), and potential drug interactions (66%), with the most interactions being metformin and amlodipine (71%).

Keywords:          Rationality, Appropriateness, Interactions, Usage Patterns, Type 2 DM

 

Abstrak

Diabetes melitus (DM) merupakan penyakit metabolik yang dapat menyebabkan kerusakan pada beberapa organ. IDF memproyeksikan peningkatan DM pada tahun 2045 menjadi 46%.  Tujuan penelitian ini untuk mengevaluasi pengobatan pasien DM tipe 2 serta potensi interaksi obat. Desain penelitian adalah observasional dan pengambilan data secara retrospektif pada resep serta rekam medik pasien DM tipe 2 di Puskesmas Banguntapan 1, bulan Januari-Februari 2023, sejumlah 125. Hasil penelitian yaitu pasien DM tipe 2 terbanyak adalah jenis kelamin perempuan (62%), usia 46-65 tahun (70%) dan penyakit penyerta hipertensi (78%). Antidibetik yang paling banyak digunakan adalah kombinasi metformin-glimepirid (83%). Kesimpulan penelitian adalah ketepatan dosis (100%), ketepatan interval waktu pemberian (98,4%), serta potensi interaksi obat (66%), dengan interaksi paling banyak adalah metformin dan amlodipin (71%).

Kata Kunci:         Rasionalitas, Ketepatan, Interaksi, Pola Penggunaan, DM tipe 2

References

[1]

International Diabetes Federation (IDF), “Facts and Figure,” 2024. [Online]. Available: idf.org/about-diabetes/diabetes-facts-figures/. [Diakses 13 Maret 2024].

[2] Kementrian Kesehatan RI, “Tetap produktif, Cegah dan Atasi Diabetes Melitus,” Jakarta, Kementerian Kesehatan RI Pusat Data dan Informasi, 2020, pp. 01-10.

[3] D. K. D. I. Yogyakarta, Profil Kesehatan D.I Yogyakarta Tahun 2021, Yogyakarta: Dinas Kesehatan Daerah Istimewa Yogyakarta, 2021.

[4] WHO, “Diabetes,” 2024. [Online]. Available: who.int/health-topics/diabetes. [Diakses 13 Maret 2024].

[5] GBD 2021 Diabetes Collabolators, “Global, Regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021,” Lancet, no. 402, pp. 203-234, 2023.

[6] D. Linkeviciute-Ulinskiene, A. Kaceniene, A. Dulskas, A. Patasius, L. Zabuliene dan G. Smailyte, “Increased Mortality Risk in People with Type 2 Diabetes Mellitus in Lithuana,” Int J Emviron Res Public Health, no. 17 (18), 2020.

[7] P. Farmaki, C. Damaskos, N. Garmpis, A. Garmpi, S. Savvanis dan E. Diamantis, “Complications of The Type 2 Diabetes Mellitus,” Curr Cardiol Rev, pp. 249-251, 2020.

[8] J. A. Alshahrani, A. S. Ali , A. M. Alhshaharani, A. M. Alshalaan, M. Alhumam dan N. Z. Alshahrani, “The Impact of Diabetes Mellitus Duration and Complications on Health-Related Quality of Life Among Type 2 Diabetic Patients in Khamis Mushit City, Saudi Arabia,” Cureus, no. 15(8), 2023.

[9] Katzung, S. B. Masters dan A. Trevor, Farmakologi Dasar dan Klinik, Jakarta: EGC, 2014.

[10] Perkumpulan Endokrinologi Indonesia, Pedoman Pengelolaan dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2021, Jakarta: PB. PERKENI, 2021.

[11] American Diabetes Association, “Classification and Diagnosis of Diabetes,” Standars of Medical Care in Diabetes , Vol. %1 dari %2S14-S31, no. 43(1), 2020.

[12] Y. M. Belayneh, T. Mamo, S. Ahmed dan Z. D. Kifle, “A retrospective study of drug related problems and contributing factors among type 2 diabetes mellitus patients on follow up at public health institutions of kemisse town, north east Ethiopia,” Metabol open, 2021.

[13] S. Fauziah, “Rasionalitas Penggunaan Oral Antidiabetes Pada Pasien Diabetes Melitus Tipe Ii Di Puskesmas Xyz Tangerang,” Jurnal Farmasi Kryonaut, no. 2(2), 2023.

[14] A. Amena, A.-h. Amal, Z. Salam, A. Sanaa, R. Samar dan E.-H. Maya, “Evaluation of Drug Related Problems in Patients with Type 2 Diabetes,” SCIENTIFIC, no. 4(3), pp. 1-11, 2022.

[15] Reutrakul, Sirimon dan Megan M. Hood, “The Relationship Between Breakfast Skipping, Chronotype, and Glycemic Control in Type 2 Diabetes,” Chronobiology, no. 31(1), pp. 64-71, 2013.

[16] E. Silva, Fernanda de Carvalho dan Femanda O Jakimiu, “Diabetics Hands: A Study On Strength and Function,” Diabetes India, pp. 1-4, 2014.

[17] A. R.F, “Faktor Resiko Kejadian Diabetes Mellitus Pada Lansia di Puskesmas Kecamatan Mampang Prapatan Jakarta Selatan Tahun 2014,” Naskah Publ Univ Indonesia, 2014.

[18] ]. J. Wang, Q. Sun dan G. Zhao, “Research progress on obesity measurement indicators and their relationship with hypertension and type 2 diabetes mellitus,” Chronic Disease Prevention and Control in China, no. 22(04), p. 488–491.

[19] Urfiyya, Q.A., 2023. POLA PERESEPAN OBAT ANTIDIABETIK PADA PASIEN DIABETES MELITUS TIPE 2 DI PUSKESMAS TEGALREJO YOGYAKARTA PERIODE OKTOBER-NOVEMBER 2022. Journal Pharmacopoeia, 2(2), pp.153-161.

[20] T. midha, V. Krishna, R. Shukla , P. Katiyar , S. Kaur , D. Martolia dan U. Pandey , “Correlation between hypertension and hyperglycemia among young adults in India,” World J Clin Cases, no. 3(2), 2015.

[21] A. Wulandari dan R. S. Melati, “Kesesuaian penggunaan obat antidiabetes pada pasien diabetes melitus di puskesmas x Palembang,” Borneo Journal of Pharmascientech, no. 5(2), 2021.

[22] R. K. Sahay, V. Mittal, G. R. Gopal, S. Kota, G. Goyal, M. Abhyankar dan S. Revenkar, “Glimepiride and Metformin Combinations in Diabetes Comorbidities and Complications: Real-World Evidence,” Cureus, 2020.

[23] Kementerian Kesehatan Republik Indonesia, “Pedoman Pelayanan Kefarmasian pada Diabates Melitus,” Kementerian Kesehatan RI, 2019.

[24] E. Wahyuningtyas, “Evaluasi Drug Related Problem (DRPs) pada Pasien Diabetes Melitus dengan Komplikasi Hipertensi di Puskesmas Dau Kbupaten Malang,” dalam Universitas Islam Negeri Maulana Malik Ibrahim, Malang, 2020.

[25] L. Kroon dan C. Zhou, “Diabetes Care,” American Diabetes Association, 2023.

[26] M. Matsuki, M. Matsuda, K. Kohara dan M. Shimoda, “Pharmacokinetics and Pharmacodynamics of Glimepiride in Type 2 Diabetic Patients: Compared Effects of Once- versus Twice-daily Dosing,” Endocrine Journal , no. 54(4), 2007.

[27] Lira C.P, “Potensi Drug Related Problems (DRPs) Penggunaan Obat Antidiabetes Pada Pasien Diabetes Melitus Tipe 2 di Instalasi Rawat Inap Rumah Sakit Kalooran Gmim Amurang,” Pharmacon, no. 6(4), 2017.

[28] K. Rawitri, S. Wahyuni dan S. R. Sari, “Analysis Of Potential Drug Interactions In Prescribing Type 2 Diabetes Mellitus Patients At A Pharmacy In Medan City,” International Journal of Health and Pharmaceutical, 2022.

[29] Departemen Kesehatan RI, “Pedoman Pengobatan Dasar di Puskesmas 2007,” Departemen Kesehatan RI, 2008.

[30] N. D. Kartikasari, “Identifikasi Potensi Interaksi Obat Antidiabetik Oral Pada Pasien Diabetes Melitus Tipe Ii Di Upt Puskesmas Sangkrah Surakarta Periode Januari – Juni 2018,” Karya Tulis Ilmiah. Program Studi DIII Farmasi Sekolah Tinggi Ilmu Kesehatan Nasional Surakarta, 2018.

[31] A. Fitriani dan S. Padmasari, “Analisis Potensi Interaksi Obat Antidiabetik Pada Pasien Diabetes Melitus Tipe 2 Rawat Inap RS PKUMuhammadiyah Gamping Yogyakarta,” Majalah Farmaseutik, no. 18(1), 2022.

[32] Ningrum VDA, Ikawati Z, Sadewa AH, Ikhsan MR, Yunilistiaingsih Y, “Patient Factors Influencing Glycemic Response to Use Metformin Monotherapy in Type 2 Diabetes Mellitus,” JMPF, no. 6(4), 2016.

[33] E. Reinhard, M. dan Ardesy Melizah, “Potensi Terjadinya Interaksi Obat Antidiabetik Oral Pada Pasien Diabetes Melitus Tipe 2 Usia Lanjut,” Sriwijaya Journal of Medicine, no. 2(3), 2019.

[34] L. R. Tuladhar, . S. . L. Shrestha, D. Regmi, S. Bimali, S. Bhusa dan P. Khadka, “Drug-drug Interactions between Hypoglycemic and Non-hypoglycemic Medication in Diabetic Patients with Comorbidities in a Tertiary Care Center: A Descriptive Cross-sectional Study,” J Nepal Med Assoc , no. 59(243), 2021.

[35] W. S. Abdulkadir, E. N. Djuwarno, N. Rasdianah, J. Akuba dan M. . F. Tahir, “Potensi Interaksi Obat Antidiabetes Melitus Tipe-2 dengan Obat Antihipertensi,” Journal Syifa Sciences and Clinical Research, no. 5(2), 2023.

[36] M. Infante, M. Leoni, M. Caprio dan A. Fabbr, “Long-term metformin therapy and vitamin B12 deficiency: An association to bear in mind,” World J Diabetes, no. 12(7), 2021.

Downloads

Published

2025-04-30

How to Cite

1.
Urfiyya QA, Azizah AR. Evaluasi Penggunaan Antidiabetik Pasien Diabetes Melitus Tipe 2 di Puskesmas Banguntapan 1: Drug Use Evaluation of Antidiabetic in Type 2 Diabetes Mellitus Patients at One of the Public Health Care in Bantul Regency. J. Sains Kes. [Internet]. 2025 Apr. 30 [cited 2026 Jun. 3];7(2):93-100. Available from: https://jsk.jurnalfamul.com/index.php/jsk/article/view/2402

Issue

Vol. 7 No. 2 (2025): J. Sains Kes.

Section

Articles

License

Copyright (c) 2025 Jurnal Sains dan Kesehatan

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.